Purely contractual global strategic alliances are an increasingly popular alternative to traditional M&A in the pharmaceutical sector. By combining resources and expertise from early‑stage research to commercialization, they can help reduce costs, accelerate development, and improve patient access. They were central to the rapid rollout of COVID‑19 vaccines, and now range from mRNA collaborations to AI‑driven health care projects. While such alliances are often pro‑competitive, they can also raise complex compliance challenges under EU antitrust law, particularly where the partners are competitors. With Europe being a critical pharmaceutical market, alliance partners must understand key EU antitrust risks and implement appropriate safeguards.

Unlike equity‑based ventures, purely contractual alliances typically do not trigger merger control, foreign direct investment or foreign subsidies filings. Nonetheless, authorities may take an interest where the alliance touches sensitive technologies or involves substantial financial contributions.

The primary legal framework is Article 101 TFEU, which prohibits agreements and concerted practices restricting competition. Because strategic alliances often involve extensive coordination, compliance with Article 101 TFEU is essential both when designing and executing the alliance.

• Antitrust-compliant design: Getting the collaboration design right is crucial for antitrust compliance and determines what is feasible in the alliance. Fortunately, EU antitrust law provides safe harbors for certain collaborations, including joint R&D and technology transfer agreements, which simplifies compliance. Yet many alliances do not fit neatly into these "pre-defined buckets" and require a tailored assessment. Even where a safe harbor applies, challenges remain: market share thresholds (e.g., 25% for joint R&D) may be difficult to determine, especially for early‑stage pipelines or multi‑indication compounds. Alliance agreements may also include potentially restrictive provisions, such as agreements on discontinuing overlapping late‑stage trials, or sales restrictions. Some collaborations must also balance granting partners sufficient access to IP and know‑how, while protecting core proprietary assets to benefit from the R&D safe harbor.
• Antitrust-compliant execution: During execution, compliance is equally important, and often even more challenging. EU antitrust law applies a strict approach to information sharing between (potentially) competing cooperation partners – stricter than the U.S. "rule of reason" – which can make the exchange of competitively sensitive information (CSI) difficult to manage, even in alliances that are pro‑competitive. CSI must therefore be managed carefully, and appropriate safeguards should be in place. This is particularly true for price‑related coordination that is relevant to market access and reimbursement, but may also extend to more technical information required for market authorization or health technology assessments. Safeguards may include alliance‑specific antitrust guidelines, and/or effective ring‑fencing measures to ensure that no unlawful information sharing takes place.

Purely contractual global strategic alliances are on the rise. To mitigate EU antitrust risks, partners must ensure an antitrust compliant setup and implement robust safeguards for its execution. Early involvement of EU antitrust experts is essential to secure the long‑term success of these collaborations.